Core Viewpoint - The company reported a revenue of $83.55 million for the six months ending June 30, 2025, reflecting a year-on-year increase of 5.88% and a profit attributable to shareholders of $19.785 million, up 5.08% year-on-year, with a proposed special dividend of HK$0.15 (approximately $0.0192) per share [1] Group 1 - The company achieved strong year-on-year growth in the U.S. market despite tariff disruptions, indicating robust demand for its quality products [1] - Emerging markets, particularly in the Asia-Pacific and Europe, Middle East, and Africa regions, have become the main growth engines for the first half of the year due to ongoing socio-economic development [1] - The growth was partially offset by a decrease in sales in the Japanese market and a decline in average selling prices in the Chinese market [1] Group 2 - The increase in net profit was primarily driven by foreign exchange gains and reduced income tax expenses, although it was offset by decreased interest income and increased selling and marketing expenses [1]
业聚医疗(06929)发布中期业绩，股东应占利润1978.5万美元，同比增加5.08%